2. Disease Areas
  3. Urogenital Disease
  4. Male Reproductive System Disease
  5. Prostatic Hyperplasia

Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate gland commonly affecting men over 40, leading to urinary symptoms such as weak urine flow, frequent urination, urgency, and potential complications like urinary retention, urinary tract infections, bladder stones, and renal impairment.

Prostatic Hyperplasia (6):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W338584
    Hydroxycitric acid tripotassium 232281-44-6 98.0%
    Tripotassium hydroxycitrate is an orally active, multi-target, multi-bioactive organic acid. Tripotassium hydroxycitrate activates Nrf2 and its downstream molecule GPX4, increases glutathione levels, and thereby inhibits ferroptosis. Tripotassium hydroxycitrate activates the Nrf2/Keap1 and ACLY/NF-κB signaling pathways, upregulates the activities of antioxidant enzymes such as superoxide dismutase, reduces MDA content, thereby alleviating oxidative stress and renal tubular epithelial cell apoptosis, and improves pulmonary vascular and right ventricular remodeling. Tripotassium hydroxycitrate activates both the AMPK and mTORC1/S6K pathways, triggers the unfolded protein response, arrests the cancer cell cycle, and induces DNA fragmentation.
    Hydroxycitric acid tripotassium
  • HY-135473
    Chlormadinone 1961-77-9 98.09%
    Chlormadinone is an orally active anti-androgen agent. Chlormadinone improves intermittency, terminal dribbling, and urinary stream size and force. Chlormadinone can be used for the research of benign prostatic hyperplasia.
    Chlormadinone
  • HY-181774
    PDE4/5-IN-1 1807631-43-1
    PDE4/5-IN-1 is a selective phosphodiesterase 4/5 (PDE4/5) dual inhibitor. PDE4/5-IN-1 functionally inhibits PDE5, PDE4B2, and PDE4D2 activity. PDE4/5-IN-1 relaxes isolated rat prostate tissue, enhances nitric oxide-induced relaxation in isolated rat prostate tissue, and reduces alpha-1 adrenoceptor-mediated contractile responses in isolated rat prostate tissue. PDE4/5-IN-1 inhibits proliferation of human hyperplastic prostate cells. PDE4/5-IN-1 can be used for the research of benign prostatic hyperplasia.
    PDE4/5-IN-1
  • HY-180815
    α1A/1D-Adrenoceptor antagonist-1 1049442-53-6 99.65%
    α1A/1D-Adrenoceptor antagonist-1 (Compound 15) is a selective α1A/1D-adrenoceptor dual antagonist with IC50 values of 20.26 and 164.9 nM. α1A/1D-Adrenoceptor antagonist-1 shows an IC50 of 1912 nM for α1B-adrenoceptor.α1A/1D-Adrenoceptor antagonist-1 can be used for research of benign prostatic hyperplasia.
    α1A/1D-Adrenoceptor antagonist-1
  • HY-W724254
    SNAP-6201 252201-38-0
    SNAP-6201 is a selective α1a adrenoceptor antagonist with a Ki of 0.2 nM. SNAP-6201 exhibits >1400-fold selectivity over α1b and α1d adrenoceptors. SNAP-6201 exhibits excellent selectively to inhibit intraurethral pressure (IUP) in the anesthetized dog model. SNAP-6201 can be used for benign prostatic hyperplasia (BPH) research.
    SNAP-6201
  • HY-183179
    α1A Adrenoceptor antagonist-1 359722-12-6
    α1A Adrenoceptor antagonist-1 is a selective α1A adrenoceptor antagonist with a human Ki <20 nM. α1A Adrenoceptor antagonist-1 exhibits activity against benign prostatic hyperplasia (BPH) to enable less hindered urine flow. α1A Adrenoceptor antagonist-1 relaxes α1a receptor-enriched urethral smooth muscle tissue without inducing hypotension. α1A Adrenoceptor antagonist-1 can be used for the research of benign prostatic hyperplasia (BPH).
    α1A Adrenoceptor antagonist-1